| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
The purpose of this study was to clarify the underlying mechanism of vertiginous attacks in Ménière's disease (MD) with a new combined animal model. Our animal model induced severe endolymphatic hydrops (EH) in the cochlea and the saccule and showed episodes of balance disorder along with spontaneous nystagmus. These findings suggest that administration of vasopressin (VP) can exacerbate EH due to acute V2; VP type 2 receptor-mediated effects, and when combined with endolymphathic sac (ES) dysfunction can cause temporary vestibular abnormalities that are similar to the vertiginous attacks in patients with MD.Systemic or local application of VP type 2 receptor antagonistist; V2 antagonist (OPC-41061), an inhibitor of the VP-AQP2 reduced EH in the cochlea and the saccule.
These results suggest that VP-AQP2 system plays an important role in the pathogenesis of MD and an inhibitor of the VP-AQP2 system will be a promising drug in the treatment of MD.
|
